Worldwide Drug Modeling Software Industry to 2027 – Increasing Adoption of Modelling Tools in Drug Discovery is Driving Growth
DUBLIN, Oct. 2, 2020 /PRNewswire/ — The “Drug Modeling Software Market Forecast to 2027 – COVID-19 Impact and Global Analysis by Product type; Application, and Geography” report has been added to ResearchAndMarkets.com’s offering.
According to this report the global drug modeling software biopharmaceutical market is expected to reach US$ 11,299.85 million by 2027 from US$ 6,205.22 million in 2019; it is estimated to grow at a CAGR of 8.1% from 2020 to 2027. The report highlights the trends prevalent in the global drug modeling software market, and the drivers and deterrents pertaining to its growth.
Based on product type, the drug modeling software market is segmented into database, software, and others. In terms of product type, the software segment held the highest share of the drug modeling software market in 2019 and is estimated to register the highest CAGR of 8.4% in the market during the forecast period. The growth of the market is attributed to the growing demand for effective therapeutics and increasing number of drug discovery efforts of various biologics across a wide range of therapeutics. Additionally, strategic activities by service providers such as collaborations, product advancement, and product launch in order to expedite drug discovery timeline are further accelerating the growth of the market.
The market growth is also attributed to a few key factors such as increasing adoption of in-silico modeling tools in drug discovery, and rising economic burden of drug discovery. However, less adoption in emerging countries is expected to hamper the growth of the market up to certain extent during the forecast period.
Crown Bioscience Inc.; Chemical Computing Group Ulc; Nimbus Therapeutics; Schrdinger, Inc.; Dassault Systmes; Genedata Ag; Biognos Ab; Compugen Ltd; Acellera ltd.; and Leadscope, Inc plc are among the prominent players operating in the drug modeling software market. The market players
Would Shareholders Who Purchased Computer Modelling Group’s (TSE:CMG) Stock Five Years Be Happy With The Share price Today?
Airport testing plan to be announced in coming days, minister suggests
The Government is preparing to shake up air travel quarantine rules as soon as this week, a Treasury minister has indicated, as he revealed officials had been studying Germany’s “best in class” testing system. Stephen Barclay, the Chief Secretary to the Treasury, said a decision would be made on airport swabbing “in the coming days”, but pointed to the testing regime in Germany, where passengers arriving from high-risk countries can be rapidly tested and allowed to leave quarantine earlier. The UK has fallen behind France and Germany, both of which introduced airport testing in August. Arrivals at some German airports can take a swap costing €130 and receive a test result within 6 hours. Alternatively, people can be released from quarantine after ten days with a free test from the Government. In the UK, all people returning from high risk countries must self-isolate for 14 days. Speaking at a ConservativeHome panel at Tory Party Conference on Saturday, Mr Barclay said testing in airports was a “key priority in the sector at the moment”. “I am expecting Grant Shapps and Matt Hancock to say more about this in the coming days,” he said. “But from a Treasury point of view, the sort of things you would expect us to be looking at is: what testing can we have at airports, and how does that interact with the quarantine rules? “What is best in class internationally? So, if we look, for example, at some of the German states, which are using testing to then release earlier from some of the restrictions.” The Telegraph understands ministers are considering forming a task force to explore various options for international travel. Mr Barclay yesterday suggested the Government was examining options for “subnational